The fermentation derived glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and [aS, 5S]-a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (Acivicin) have been shown to possess promising antitumour activity against a wide variety of animal and human xenografted solid tumours including colon, breast and lung carcinomas (Ovejera et al., 1979; Houchens et al., 1979; Duvall, 1960) . These analogues of glutamine, however, have limited potential when used as single agents in the treatment of cancer in man because of severe toxicity that prevents dose escalation into the required therapeutic range (Sklaroff et al., 1980; Weiss et al., 1982; LePage & Loo, 1973) . Co-administration of glutamine reduces markedly the concentration of glutamine in the tumour-bearing host making it possible to utilize considerably lower doses of the analogue, and this has resulted in improvement of the therapeutic index (Roberts & Rosenfeld, 1980; Roberts et al., 1979; Holcenberg, 1979) . Treatment with glutaminase alone was shown to inhibit growth of a variety of ascites tumours and leukaemias, but had only slight efficacy against experimental solid tumours (Roberts et al., 1979; Schmid & Roberts, 1974; Mitta et al; . In order to ascertain the extent to which the therapeutic efficacy of glutamine antimetabolites may be enhanced by glutamine depletion we studied the effects of glutamine antagonists on DNA synthesis and cell cycle phase distributions in normal and malignant cells in culture.
The human cell lines studied were Redmond colon tumour (doubling time, 1.7 days), and A549 lung tumour (dt, 1.7 days), obtained from the Memorial Sloan-Kettering Cancer Center, colon tumour cell lines CX-1 (dt, 1.2 days) and CX-2 (dt, 1.2 days), and lung tumour 1.4 (Roberts, 1976) . The glutamine-depleted medium consisted of RPMI lacking glutamine and containing 10% dialyzed FCS. After incubation with acivicin, DON, glutaminase or glutamine-depleted medium (with and without drugs) for 48 h, or with acivicin or DON in medium with glutamine for 2 h, 1 1Ci m l radiolabelled [methyl-3H]-thymidine (NEN, Boston, MA) was added to the cell cultures. Inhibition of DNA synthesis which has been shown to reflect the cellular sensitivity to the cytotoxic effects of the drugs was monitored as described in a previous study (Rosenfeld & Roberts, 1981) . Dose response (0.6-60 MM of drugs) was routinely monitored for all cell lines tested after 2 h incubation with the drugs and 0-90% inhibition could be observed within this range. Table I shows the sensitivity of different cell lines to the analogues. Sensitivities are expressed as concentration of analogues causing 50-60% inhibition of DNA synthesis as compared to untreated controls. The values summarize the results of two independent experiments each performed in duplicate. As shown in Table I , the tumour cell lines tested were 3-10 times more sensitive to DON and 2-6 times more sensitive to acivicin than was the normal lung fibroblast IMR-90 cell lines.
In order to ascertain what effects glutamine depletion and glutamine antimetabolites would exert upon cell cycle phase distribution, cells were incubated for 48 h with either glutamine-depleted medium, glutaminase (0.01 I.U. or 0.1 IUml-1), DON or acivicin (6 or 30 pM). These concentrations of drugs completely inhibited growth of all cell lines tested but cell viability was still unaffected (>90%). Nuclei were isolated as described , stained with 50 pg ml-' propidium iodide, and cell cycle analysis was performed on a Coulter Electronics Epics V flow cytometer (Coulter Electronics, Inc., Hialeah, FL.). The instrument was adjusted to achieve coefficients of variation for the nuclei of usually 3-5%. The proportion of 10,000 nuclei in G1, S, and G2-M was calculated using the Para 1 data analysis program of the flow cytometer. Figure 1 shows representative histograms obtained with the normal The cells were preincubated for 2 h with the drug before
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